Maximum of 700,000 shares to be acquired, up to 3.13% of issued shares, total amount up to 2,000,000,000 yen, during the period from 2026\/08\/12 to 2026\/09\/07.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2664-20260803-01.pdf","jir_short_summary":"Maximum of 700,000 shares to be acquired, up to 3.13% of issued shares, total amount up to 2,000,000,000 yen, during the period from 2026\/08\/12 to 2026\/09\/07.","jir_summary":"### Purpose and overview of the share buyback\nThe company has decided to acquire treasury stock to enhance shareholder value, strengthen shareholder returns, and execute a flexible capital policy. The target is our ordinary shares, with an upper limit of 3.13% of issued shares and a total amount cap of 2,000,000,000 yen. The acquisition period is from August 12, 2026 to September 7, 2026.\n\n### Background and impact\nThe treasury stock acquisition is positioned to improve financial policy flexibility and offset dilution as part of the shareholder return policy. At this time, any other financial indicators or direct impact on performance are not known from this disclosure.","jir_financial_highlights":"Total number of shares to be acquired: 700,000 shares (Upper limit)\nAggregate acquisition value: 2,000,000,000 yen (Upper limit)\nAcquisition period: 2026 August 12 \u2013 2026 September 7 (Period setting)","jir_category":"","jir_hashtags":"#KawachiPharmaceutical, #ShareBuyback, #IR","jir_key_figures":"Type of shares to be acquired: Our common stock\nTotal number of shares that can be acquired: 700,000 shares (3.13%)\nTotal acquisition value: 2,000,000,000 yen\nAcquisition period: 2026 August 12 \u2013 2026 September 7","jir_meta_title":"Kawachi Pharmaceutical \u2013 Decision to Acquire Treasury Stock | Aug\u2013Sept 2026","jir_meta_description":"Kawachi Pharmaceutical decides to acquire treasury stock. Upper limit 700,000 shares, upper limit 2.0 billion yen, acquisition period 2026\/8\/12\u20139\/7. Strengthening shareholder returns and capital policy agility.","jir_og_title":"Kawachi Pharmaceutical \u2013 Decision to Acquire Treasury Stock | Aug\u2013Sept 2026","jir_og_description":"Kawachi Pharmaceutical decides to acquire treasury stock. Summary of upper limits for shares, amount, and period.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-93411","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n